RARE CANCERPregnancy-relatedWHO 5th Edition Classification

Gestational Trophoblastic Neoplasia

Rare Malignancy (< 6 cases per 100,000 / year) • Clinical Staging, Genomic Targets & Vetted Specialists

A group of tumours arising from placental tissue after any pregnancy, including complete and partial hydatidiform mole, invasive mole, choriocarcinoma, placental site trophoblastic tumour and epithelioid trophoblastic tumour. It is one of the few metastatic solid cancers that is reliably curable with chemotherapy, and hCG provides an exceptionally accurate tumour marker for both diagnosis and monitoring.

Request Rare Cancer Tumor Board Find NCI Treatment CentersAsk Vani AI Navigator

Emergent Referral AdvisoryImmediate Action

Certain rare malignancies progress rapidly or carry acute risk of airway obstruction, acute spinal compression, hydrocephalus, or biopsy-seeding. Do not perform needle biopsy or surgery outside of an NCI-designated specialty sarcoma or neuro-oncology unit without multidisciplinary tumor board review.

Report immediately to an emergency department or tertiary oncologist upon:

  • Any hCG plateau or rise after pregnancy - refer to a trophoblastic disease centre
Who It Affects

People of reproductive age after any pregnancy; risk rises at the extremes of maternal age

Annual Incidence

Roughly 1 in 1,000 pregnancies for molar pregnancy; higher in parts of Asia

Clinical Evidence Review

Last audited: 2026-08-13 against NCCN, ESMO, and WHO 5th ed. guidelines.

Clinical Presentation & Hallmark Symptoms

Presenting signs most frequently observed across clinical case series

Vaginal bleeding after a pregnancy, miscarriage or molar pregnancy
A uterus larger than expected for dates
hCG that fails to fall, or rises, after pregnancy ends
Severe nausea and vomiting, or early pre-eclampsia in molar pregnancy
Cough or breathlessness from lung metastases; headache or seizures from brain spread

Genomic Profiling & Defining Molecular Lesions

Critical diagnostic fusions, somatic mutations, and therapeutic targets

Rare malignancies frequently depend on distinct oncogenic drivers rather than conventional environmental carcinogens. Comprehensive Next-Generation Sequencing (NGS comprehensive panel) and FISH/IHC are mandatory to establish the true diagnosis and screen for basket trial agents.

Serum beta-hCG - the defining markerp57 immunostaining to distinguish complete from partial mole

Standard-of-Care Treatment Protocol

Frontline and multimodal strategies established under international consensus guidelines

1

Suction evacuation of the uterus for molar pregnancy

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

2

Single-agent methotrexate or actinomycin-D for low-risk disease (FIGO score 0-6)

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

3

EMA-CO combination chemotherapy for high-risk disease (score 7 or above)

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

4

Surgery for placental site and epithelioid trophoblastic tumours, which are chemo-resistant

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

5

Structured hCG surveillance after treatment, with contraception during follow-up

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

Clinical Trial Advisory: For rare and ultra-rare malignancies, enrollment in an active clinical trial or expanded-access program is widely considered the preferred standard of care by ASCO and NCCN panels.

Prognosis & Disease Trajectory

Objective clinical outlook without false reassurance

Excellent, and among the best of any metastatic malignancy. Low-risk disease is cured in essentially all patients, and high-risk disease has cure rates above 90% with combination chemotherapy. Fertility is usually preserved. Ultra-high-risk and placental site tumours are the exceptions.

Note: Statistics reflect cohort averages. Individual outcomes depend heavily on performance status, resectability, biomarker expression, and timely access to specialized tertiary care.

Active Research, Biomarkers & Clinical Trials

Novel investigational agents, phase I/II trials, and international rare disease consortia

Immune checkpoint inhibitors, notably pembrolizumab and avelumab, have shown activity in chemoresistant disease and are being incorporated into salvage protocols - an important development for the small refractory group.

Need Help Matching to an Active Rare Cancer Trial?

ByOnco scans ClinicalTrials.gov, NCI trial networks, and institutional registries for open patient cohorts.

Request Trial Match
Expert Clinicians

Verified Specialists for Gestational Trophoblastic Neoplasia

Browse All Oncologists

Dr. Neil Horowitz

Director of Clinical Research in Gynecologic Oncology

20+ yrs exp

Dana-Farber Cancer Institute

Boston, USA

Gynecologic OncologyGTNTrophoblastic Disease Center
Vetted DirectoryConsult Specialist

Dr. Ann Tan

Senior Consultant OBGYN

30+ yrs exp

Mount Elizabeth

Singapore, Singapore

OBGYNMolar PregnanciesGTN
Vetted DirectoryConsult Specialist

Prof. Michael J. Seckl

Medical Oncologist

25+ yrs exp

Charing Cross Trophoblast Center

London, United Kingdom

Medical OncologyGTNClinical Trials
Vetted DirectoryConsult Specialist

Dr. Niranjan Chavan

Gynecologic Oncologist

20+ yrs exp

King Edward Memorial Hospital

Mumbai, India

Gynecologic OncologyHigh-risk GTNCombination Chemotherapy
Vetted DirectoryConsult Specialist
Hospital Network

Designated Cancer Centers with Dedicated Programs

Search All 72 NCI Centers

Memorial Sloan Kettering Cancer Center

NY

NCI-Designated Comprehensive Cancer Center

World-leading rare tumor board & pediatric solid tumor protocols

Proton TherapyCAR-T Cell TherapyRobotic Surgery
1,000+ Active Clinical TrialsView Center Profile

University of Texas MD Anderson Cancer Center

TX

NCI-Designated Comprehensive Cancer Center

Largest specialized rare cancer and sarcoma multidisciplinary program

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
1,200+ Active Clinical TrialsView Center Profile

Dana-Farber / Harvard Cancer Center

MA

NCI-Designated Comprehensive Cancer Center

Pioneering genomic molecular tumor boards & rare histologies

Proton TherapyCAR-T Cell TherapyPhase I Unit
1,100+ Active Clinical TrialsView Center Profile

Mayo Clinic Comprehensive Cancer Center

MN

NCI-Designated Comprehensive Cancer Center

High-volume surgical oncology & rare endocrine/neuroendocrine expertise

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
600+ Active Clinical TrialsView Center Profile

Frequently Asked Clinical Questions

Authoritative guidance on diagnosis, tumor boards, genomic markers, and care options

Related Rare Malignancies in Catalog

rare

Cancer of Unknown Primary (CUP)

rare

Malignant Mesothelioma

rare

Retinoblastoma

rare

Ewing Sarcoma

Independent Tumor Board Review

Facing a Diagnosis of Gestational Trophoblastic Neoplasia?

Rare cancers demand rare expertise. Connect your medical records to US NCI-fellowship trained oncologists, subspecialist pathologists, and active clinical trial investigators within 12 to 72 hours.

Upload Scans for Second Opinion Schedule Virtual Teleconsult